The 5 analysts offering 12-month price forecasts for Erytech Pharma SA have a median target of 23.36, with a high estimate of 29.73 and a low estimate of 13.00. The median estimate represents a +418.06% increase from the last price of 4.51.
The current consensus among 6 polled investment analysts is to Buy stock in Erytech Pharma SA. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.94
Reporting Date Mar 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.